title: Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism.
abstract: Zopiclone is a widely prescribed, nonbenzodiazepine hypnotic that is extensively metabolized by the liver in humans. The aim of the present study was to identify the human cytochrome P-450 (CYP) isoforms involved in zopiclone metabolism in vitro. Zopiclone metabolism was studied with different human liver microsomes and a panel of heterologously expressed human CYPs (CYP1A2, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, and 3A4). In human liver microsomes, zopiclone was metabolized into N-desmethyl-zopiclone (ND-Z) and N-oxide-zopiclone (NO-Z) with the following K(m) and V(m) of 78 +/- 5 and 84 +/- 19 microM, 45 +/- 1 and 54 +/- 5 pmol/min/mg for ND-Z and NO-Z generation, respectively. Ketoconazole (CYP3A inhibitor) inhibited approximately 40% of the generation of both metabolites, sulfaphenazole (CYP2C inhibitor) inhibited the formation of ND-Z, whereas alpha-naphtoflavone (CYP1A), quinidine (CYP2D6), and chlorzoxazone (CYP2E1) did not affect zopiclone metabolism. The generation of ND-Z and NO-Z were highly correlated to testosterone 6beta-hydroxylation (CYP3A activity, r = 0.95 and 0.92, respectively; p =.0001), and ND-Z was highly correlated to CYP2C8 activity (paclitaxel 6alpha-hydroxylase; r = 0.76, p =.004). Recombinant CYP2C8 had the highest enzymatic activity toward zopiclone metabolism into both its metabolites, followed by CYP2C9 and 3A4. CYP3A4 is the major enzyme involved in zopiclone metabolism in vitro, and CYP2C8 contributes significantly to ND-Z formation.
authors.affiliation: Clinical Pharmacology Unit, Saint Antoine University Hospital, School of Medicine Paris 6, France. becquemo@b3e.jussieu.fr
authors.forename: L
authors.initials: L
authors.lastname: Becquemont
authors.forename: S
authors.initials: S
authors.lastname: Mouajjah
authors.forename: O
authors.initials: O
authors.lastname: Escaffre
authors.forename: P
authors.initials: P
authors.lastname: Beaune
authors.forename: C
authors.initials: C
authors.lastname: Funck-Brentano
authors.forename: P
authors.initials: P
authors.lastname: Jaillon
mesh_terms: D053961:Azabicyclo Compounds; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D003640:Dealkylation; D006801:Humans; D006993:Hypnotics and Sedatives / Q000378:metabolism*; D066298:In Vitro Techniques; D007202:Indicators and Reagents; D007700:Kinetics; D008862:Microsomes, Liver / Q000201:enzymology*; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D010084:Oxidation-Reduction; D010879:Piperazines / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D015003:Yeasts / Q000378:metabolism
chemical_list: D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D007202:Indicators and Reagents; D010879:Piperazines; D011994:Recombinant Proteins; C515050:zopiclone; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; C053553:tolbutamide 4-hydroxylase